Latest News

Launch of Mucodis® Dermal Spray
Mucodis® Dermal Spray

Launch of Mucodis® Dermal Spray

Quantum Pharma Plc (AIM:QP.), the growing, service-led niche pharmaceutical manufacturer, developer and supplier to the health and care sectors, is pleased to announce that Colonis, part of its recently formed Niche Pharmaceuticals division, has launched Mucodis® Dermal Spray. The spray is part of the Mucodis® range of in-licensed patented medical devices, which focus on treating some of the side effects experienced by patients undergoing the treatment of cancer.

Mucodis® Dermal Spray helps to prevent and treat radiation-induced dermatitis ("Radiodermatitis"). Radiodermatitis is a side effect of radiotherapy which can cause a range of dermal disorders from inflammation of the skin to the development of necrosis and skin peeling. The development and severity of radiodermatitis depends on multiple patient and treatment factors which include the total radiation dose administered, the duration of radiotherapy, and concomitant treatment with chemotherapy1. All patients receiving radiotherapy are therefore at a potential risk of developing some degree of radiodermatitis with approximately 85% of patients experiencing a moderate to severe skin reaction2.

352,000 patients in the UK are diagnosed annually with cancer and many experience painful or unpleasant side effects as they progress with their treatment3. The Mucodis® range provides the NHS with prescribable products to address a number of the side effects associated with cancer treatments including mucositis, radiation-induced dermatitis, vulvovaginitis and proctitis. Colonis has been granted an exclusive distribution licence for these products for five years, with an option to extend beyond this initial period.

Andrew Scaife, Chief Executive of Quantum Pharma Plc, commented: "Radiodermatitis is an unpleasant and painful side effect of cancer treatment and we are delighted to launch Mucodis® Dermal Spray to help treat these symptoms. We are excited by the potential that the Mucodis® range offers the NHS and patients. There is a clear unmet need for this type of relief and we are confident that our products will have a significant effect on improving the patient's quality of life."

Footnotes:

1. https://www.ons.org/practice-resources/pep/radiodermatitis

2. Salvo, N. et al. Prophylaxis and management of acute radiation-induced skin reactions: A systematic review of the literature. Curr Oncol. 2010: 17(4); 94-112.

3. Cancer Research UK (accessed June 2016)

Posted by: Quantum Webmaster on 13th July 2016